Viewing Study NCT05757206


Ignite Creation Date: 2025-12-26 @ 3:59 PM
Ignite Modification Date: 2025-12-29 @ 6:43 AM
Study NCT ID: NCT05757206
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-01-15
First Post: 2023-02-17
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: The Syn-Sleep Study
Sponsor: CND Life Sciences
Organization:

Study Overview

Official Title: Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In collaboration with approximately 8 centers that specialize in iRBD we will recruit a total of 80 individuals for the study. All subjects will be enrolled into a 2-year longitudinal study where skin biopsies will be performed at 3 sites on each patient at 12-month intervals (baseline, year 1, year 2). Plasma blood collection will be performed at 12-month intervals (baseline, year 1, year 2). Detailed quantified examination, cognitive evaluation, medical history, and questionnaires will be performed at each visit. Additional biomarker, imaging and clinical information (if available) will be obtained for the purpose of determining phenoconversion to clinically apparent synucleinopathy.

Subjects enrolled in the study will have baseline evaluations and follow up visits at 12 and 24 months to define any changes to clinical diagnosis (clinical phenoconversion). Skin biopsies will be repeated at the 12- and 24-month follow up visits to determine the rate of P-SYN accumulation over time and the rates of nerve fiber degeneration within punch skin biopsies.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: